- |||||||||| fludarabine IV / Generic mfg.
Journal: Proteomic Analysis Reveals a Novel Therapeutic Strategy Using Fludarabine for Steroid-Resistant Asthma Exacerbation. (Pubmed Central) - May 6, 2022
Further, the pharmacological drug Fludarabine decreased STAT1 expression, restored the responsiveness of OVA/FLU mice to DEX and markedly suppressed disease severity. Taken together, this study describes the proteomic profile underpinning molecular mechanisms of FLU-induced asthma exacerbation and identifies STAT1 as a potential therapeutic target, more importantly, we provided a novel therapeutic strategy that may be clinically translated into practice.
- |||||||||| Biomarker, Review, Journal: Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis. (Pubmed Central) - May 6, 2022
Taken together, this study describes the proteomic profile underpinning molecular mechanisms of FLU-induced asthma exacerbation and identifies STAT1 as a potential therapeutic target, more importantly, we provided a novel therapeutic strategy that may be clinically translated into practice. This study provides a current summary of prognostic indicators of disease progression in DMD, which will help inform the design of comparative analyses and future data collection initiatives in this patient population.
- |||||||||| Motrem (nangibotide) / Inotrem
Multiparametric Circulating Cardiovascular Biomarkers Elucidate A Molecular Signature Of Coronavirus Disease 2019 Mortality And Identify Vascular Barrier Stabilizing Therapies (Grand Ballroom D) - May 6, 2022 - Abstract #ATVBPVDGPM2022ATVB_PVD_GPM_34;
ECs treated with patient plasma showed increased vascular permeability, which was ameliorated by treatment with the vascular stabilizing molecules angiopoietin-1 mimetic or recombinant Slit2-N, but not nangibotide or dexamethasone. Conclusions : Integration of multi-omics data identified microRNA and vascular biomarkers prognostic of in-hospital mortality in COVID-19 patients and revealed that vascular stabilizing therapies should be explored as a treatment for endothelial dysfunction in COVID-19, and other severe diseases where endothelial dysfunction has a central role in pathogenesis.
- |||||||||| hydrocortisone / Generic mfg.
Journal: Baseline and Peak Cortisol Response to the Low-Dose Short Synacthen Test Relates to Indication for Testing, Age, and Sex. (Pubmed Central) - May 6, 2022
336 (70%) patients had a normal response (baseline cortisol >100 nmol/L, peak >450 nmol/L), 78 (16%) a suboptimal response (peak cortisol 350-450 nmol/L) and were prescribed hydrocortisone to during periods of stress only, 67 (14%) an abnormal response (baseline <100nmol/L or peak <350nmol/L) and were prescribed daily hydrocortisone...Abnormal results occurred most frequently in patients treated previously with pharmacological doses of glucocorticoids or structural brain abnormalities (P < .001). The low prevalence and strong association of abnormal results with indication for testing, suggests that over diagnosis occurred infrequently in this clinical setting.
- |||||||||| hydrocortisone / Generic mfg.
Journal: A Novel Homozygous MC2R Variant Leading to Type-1 Familial Glucocorticoid Deficiency. (Pubmed Central) - May 6, 2022
At 18 months of age, low serum cortisol was found, and he was started on hydrocortisone replacement therapy...Homozygous semiconserved p.Leu109Gln mutation disrupts cAMP production and MC2R protein expression leading to ACTH resistance. This study provides additional evidence that this novel pathogenic variant in MC2R results in FGD phenotypes.
- |||||||||| hydrocortisone / Generic mfg.
Journal: Adrenal gland haemorrhages following motor vehicle accident with resultant adrenal insufficiency. (Pubmed Central) - May 6, 2022
All were commenced on stress dose hydrocortisone replacement with improvement in clinical status...Biochemical assessment of the adrenocortical axis should be considered in all patients presenting with high-impact trauma following motor vehicle accidents. Given the potential for delayed presentation, any patients with new haemodynamic instability should have repeat biochemistry and/or imaging performed, even if initial adrenal imaging and investigations were normal.
- |||||||||| dexamethasone / Generic mfg., hydrocortisone / Generic mfg.
Journal: Glucocorticoid-induced adrenal insufficiency: an uncommon cause of hypercalcaemia. (Pubmed Central) - May 6, 2022
Further inquiry revealed that the patient had taken over-the-counter dexamethasone on a regular basis for allergic rhinitis for more than 2 years and had stopped 2 weeks prior to the onset of symptoms...The patient was resuscitated with intravenous fluids and replacement doses of oral hydrocortisone were started with a plan of prolonged tailing off to allow the endogenous adrenal function to recover...Adrenal insufficiency should be considered in the differential diagnosis of parathyroid hormone-independent hypercalcaemia. A thorough clinical history is of paramount importance in arriving at the correct diagnosis.
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Assessment of Gene Therapy Treatment in the Pompe Disease Canine Model (Room 204) - May 6, 2022 - Abstract #ASGCT2022ASGCT_1705;
On the day of dosing, prior to gene therapy delivery, a dose of diphenhydramine (1mg/kg) is given subcutaneously (SQ) followed by anti-thymocyte globulin (rabbit) (3mg/kg) intravenously (IV) and then Solu-Medrol (1mg/kg) IV...These results support the potential use of a dual vector administration to establish tolerance to GAA which is critical in IOPD. Additional studies are underway using pre-treatment with a canine specific anti-CD20 antibody to block anti-capsid antibody responses and allow subsequent dosing to maintain GAA level in the growing musculature over the life span.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Glucocorticoid Dosing in Induction Remission Treatments for ANCA-Associated Vasculitis (Mini-Orals Hall) - May 5, 2022 - Abstract #ERAEDTA2022ERA_EDTA_1077;
High dose GC treatment was defined as 1.5 g intravenous (IV) methylprednisolone over 3 days followed by a tapering course of oral prednisolone starting with 60 mg per day...Our small size study suggests a lower dose GC induction remission treatment regime to be safe, effective and associated with fewer adverse effects relating to GC toxicity. Further large studies are needed to look at the narrow therapeutic window of GC and the role of GC-sparing treatments so as to improve outcomes in these patients.
- |||||||||| dexamethasone / Generic mfg.
COVID-19 Associated Collapsing Variant of Focal Segmental Glomerulosclerosis: A Case Series of 7 Patients from a Single UK Centre (Mini-Orals Hall) - May 5, 2022 - Abstract #ERAEDTA2022ERA_EDTA_1070;
Management of glomerulopathy was supportive in all cases, including diuresis and anticoagulation (two patients received a short course of oral dexamethasone for their COVID-19 symptoms)...Partial remission was achieved in most of our cases with supportive treatment only; however, ongoing monitoring of this cohort is required to better understand longer-term patient outcomes. Testing for APOL-1 gene mutations and molecular testing of biopsy samples for this cohort is also ongoing to facilitate better insights into pathophysiology and risk factors associated with this novel disease.
- |||||||||| cisplatin / Generic mfg.
Renal Outcomes in High Dose Cisplatin in Locally Advanced Squamous Cell Cancer of the Head and Neck: A Monocentric Experience (Mini-Orals Hall) - May 5, 2022 - Abstract #ERAEDTA2022ERA_EDTA_1012;
All patients received adequate supportive care such as SF 750 mL + 16 mEq MgSO4 IV 200 mL/h before and after cisplatin administration (a total of 1500 mL at day 0 and again at day 1), with 375 mL mannitol 10% if diuresis after hydration was less than 100–200 mL/h and dexamethasone 12 mg IV as chemo premedication at day 0 and 8 mg PO at days 1 to 3 as antiemetic prophylaxis followed by 6 days of steroid progressive decalage. FIGURE 2: AKI incidence was 14% with a significative difference between patients with baseline eGFR > 90 mL/min and patients with eGFR 90 mL/min and patients with eGFR < 90.
- |||||||||| dexamethasone / Generic mfg., piperacillin sodium/tazobactam sodium / Generic mfg.
Vitamin C Nephrotoxicity in a COVID-19 Patient: A Case Report (Mini-Orals Hall) - May 5, 2022 - Abstract #ERAEDTA2022ERA_EDTA_937;
CONCLUSION Vitamin C is an anti-inflammatory treatment used in COVID-19 that can lead to secondary hyperoxaluria with significant and irreversible AKI. Due to the severity of AKI in patients with preexisting CKD, we believe renal function should be considered before using high doses of vitamin C. Larger controlled trials are needed both to establish the clinical benefit of vitamin C and further describe its potential nephrotoxicity.
- |||||||||| dexamethasone injection / Generic mfg.
Atypical Haemolytic Uremic Syndrome Associated with COVID-19: Case Report (Mini-Orals Hall) - May 5, 2022 - Abstract #ERAEDTA2022ERA_EDTA_922;
He was treated with broad spectrum antibiotics, intravenous dexamethasone and supportive therapy...The patient was hospitalized for 21 days. CONCLUSION Close monitoring and early intervention can help for a better outcome of SARS-CoV-2 patients complicated with aHUS.
- |||||||||| Tarpeyo (budesonide) / Calliditas, Stada
NEFECON® (BUDESONIDE) IS AN EPIGENETIC MODIFIER IN IGA NEPHROPATHY (Hall S03) - May 5, 2022 - Abstract #ERAEDTA2022ERA_EDTA_561;
P2
Treatment with Nefecon ® 16 mg/day for 9 months selectively downregulated exosomal miR-122-5p, while having no effect on exosomal miR-483-5p levels, arguing against a generalized ‘anti-miR’ effect of Nefecon ® . Studies are ongoing to both precisely delineate the cellular source(s) of these exosomes and determine the downstream impact of these changes on glomerular and tubulointerstitial biology.
- |||||||||| Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck
What Is the Right Antipsychotic? Decision Making Challenges in a Patient With Schizoaffective Disorder and Pituitary Macroadenoma () - May 5, 2022 - Abstract #APA2022APA_721;
After a few days of initial medication refusal, he agreed to commence a regimen of valproate 1000 mg/day and olanzapine 5mg by mouth at nighttime, which was discontinued at the time of discharge, hormonal replacement of levothyroxine 75 mcg/day, hydrocortisone 25 mg/day in divided doses, and androgen gel 1% after consultation with the endocrinology team...Prior to discharge, he agreed to receive aripiprazole long acting injectable 300mg...(2) Our choice of aripiprazole has been validated in a well-reviewed meta-analysis of being the first choice to be considered for lowering prolactin concentrations in patients with a psychotic disorder and hyperprolactinemia. (3)
- |||||||||| olanzapine / Generic mfg.
The Curious Case of Olanzapine-Induced Hypoglycemia () - May 5, 2022 - Abstract #APA2022APA_664;
It took about 10 days for his glucose to normalize and eventually hydrocortisone was stopped...After his glucose levels normalized, he was transitioned to haloperidol...In this case the patient took a high dose of olanzapine leading to delirium and hypoglycemia. Given the life-threatening potential of hypoglycemia, we suggest regular monitoring of glucose levels in patients presenting with olanzapine overdose.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Seronegative Autoimmune Encephalitis: A Case Report () - May 5, 2022 - Abstract #APA2022APA_634;
Psychotic symptoms and associated psychiatric/neurologic complaints resolved following treatment with Solumedrol 1000 mg IV x 3-5 days on multiple presentations...Negative antibody testing does not rule out the presence of the condition as antibodies can remain absent or develop later in the disease course, and both imaging and other laboratory studies are frequently unremarkable. Given that rapid treatment of AE can result in quick and complete resolution of psychotic and neurologic symptoms, clinicians must maintain a low threshold for diagnosis and treatment despite lack of supporting studies.
- |||||||||| prednisone / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Clinical Vignette: A Rare Case of LGI-1 Encephalitis Presenting as Schizophreniform Disorder () - May 5, 2022 - Abstract #APA2022APA_409;
He demonstrated improvements in memory, hallucinations, and dystonic arm movements, and after being tapered off methylprednisolone, he was discharged on prednisone...One study shows that prognosis for such cases improves greatly if detected and treated before severe cognitive decline, it is recognized in patients without typical criteria of encephalitis, and aggressive immunotherapy is begun.3 Prognosis for most patients is good, with up to 80% experiencing resolution of symptoms after treatment. This patient case demonstrates the similar clinical presentation between encephalitis and schizophrenia, both of which are treated vastly differently.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
A Case of Chronic Hashimoto Encephalopathy With Delayed Treatment Due to Psychiatric Symptoms () - May 5, 2022 - Abstract #APA2022APA_319;
However, over the next several months she presented several times with worsening manic and psychotic symptoms including elevated mood, flight of ideas, increased speech rate, decreased need for sleep, excessive spending, grandiose delusions, and paranoia and was diagnosed with bipolar disorder and started on lithium, olanzapine, and lorazepam though ultimately only improved after index course of electro-convulsive treatment (ECT)... This case highlights the importance of proper diagnosis and treatment of chronic Hashimoto encephalopathy despite underlying psychiatric symptoms.
- |||||||||| Decadron (dexamethasone) / Merck (MSD)
Trial completion date: Carfilzomib, Clarithromycin (Biaxin (clinicaltrials.gov) - May 5, 2022
P2, N=74, Active, not recruiting,
Active, not recruiting --> Completed Trial completion date: Mar 2022 --> Mar 2023
- |||||||||| hydrocortisone / Generic mfg.
Journal: Determination of 44 foodborne stimulants and 6 progestogens in meat by QuEChERS and ultra-performance liquid chromatography-tandem mass spectrometry (Pubmed Central) - May 5, 2022
The content ranges and detection rates of the compounds were as follows: hydrocortisone: 3.3-22.6 μg/kg, 100%; cortisone: 1.5-2.1 μg/kg, 67%; androstenedione: 0.7-1.2 μg/kg, 17%; and testosterone: 0.6-1.5 μg/kg, 42%. In conclusion, the proposed method is simple, accurate, and sensitive, and hence, is suitable for the detection of foodborne stimulants and progestogens in different kinds of raw meat.
- |||||||||| dexamethasone / Generic mfg.
Journal: Characteristics of aldosterone-producing adenomas in patients without plasma renin activity suppression. (Pubmed Central) - May 5, 2022
The unsuppressed PRA group had higher morning cortisol levels (12.6 [8.5, 13.5] vs. 8.5 [7.1, 11.0] μg/dL, P = 0.03) and higher cortisol levels after a 1 mg dexamethasone suppression test (DST) (2.2 [1.6, 2.5] vs. 1.3 [1.0, 1.9] μ g/dL, P = 0.004) than the suppressed PRA group...These findings suggest that PA should not be ruled out by unsuppressed PRA among patients with hypertension, particularly when their cortisol levels remain unsuppressed in the 1 mg DST. Meanwhile, it should be acknowledged that patients with unsuppressed PRA have higher aldosterone levels on the non-surgical side, and a lower likelihood of postoperative complete clinical success is to be expected.
- |||||||||| SEA-BCMA / Seagen
Enrollment change, Trial completion date, Trial primary completion date: SGNBCMA-001: A Safety Study of SEA-BCMA in Patients With Multiple Myeloma (clinicaltrials.gov) - May 5, 2022
P1, N=131, Recruiting,
Meanwhile, it should be acknowledged that patients with unsuppressed PRA have higher aldosterone levels on the non-surgical side, and a lower likelihood of postoperative complete clinical success is to be expected. N=305 --> 131 | Trial completion date: Jul 2023 --> Feb 2026 | Trial primary completion date: Jan 2023 --> Feb 2025
- |||||||||| mezagitamab (TAK-079) / Takeda
Trial completion, Enrollment change, Trial completion date: A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) (clinicaltrials.gov) - May 5, 2022
P1/2, N=50, Completed,
N=305 --> 131 | Trial completion date: Jul 2023 --> Feb 2026 | Trial primary completion date: Jan 2023 --> Feb 2025 Active, not recruiting --> Completed | N=100 --> 50 | Trial completion date: Dec 2022 --> Jan 2022
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed, Trial completion date, Trial primary completion date: Treg Modulation With CD28 and IL-6 Receptor Antagonists (clinicaltrials.gov) - May 5, 2022
P1/2, N=10, Active, not recruiting,
Active, not recruiting --> Completed | N=100 --> 50 | Trial completion date: Dec 2022 --> Jan 2022 Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Apr 2024 | Trial primary completion date: Jun 2022 --> Sep 2022
- |||||||||| dexamethasone / Generic mfg.
Enrollment closed: AVS After 1mg DST to Determine Subtype in PA (clinicaltrials.gov) - May 5, 2022
P=N/A, N=86, Active, not recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Apr 2024 | Trial primary completion date: Jun 2022 --> Sep 2022 Recruiting --> Active, not recruiting
- |||||||||| Ocrevus (ocrelizumab) / Roche, Biogen
Enrollment open, Head-to-Head: Ocarina II: A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (clinicaltrials.gov) - May 5, 2022
P3, N=232, Recruiting,
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| dexamethasone / Generic mfg., moxifloxacin intravenous / Generic mfg.
A MYCOBACTERIUM BOVIS CATASTROPHE (E-Poster Stations) - May 4, 2022 - Abstract #ESPID2022ESPID_695;
CSF subsequently cultured M. bovis and therapy was changed to moxifloxacin, ethambutol, rifampicin and isoniazid...Learning Points/ This unusual cluster highlights that, although rare, transmission of M. Bovis infection from domestic cats to humans can occur. Identification of M. bovis in a domestic pet should trigger screening of close human contacts for possible infection.
- |||||||||| triamcinolone acetonide / Generic mfg.
Trial completion date, Trial primary completion date, Surgery: TRICEPS: Triamcinolone Injections for Persistent Choroidal Effusions Post Glaucoma Surgery (clinicaltrials.gov) - May 4, 2022
P4, N=20, Recruiting,
Trial completion date: Jan 2022 --> Jan 2025 | Trial primary completion date: Dec 2020 --> Dec 2024 Trial completion date: Feb 2022 --> Dec 2024 | Trial primary completion date: Nov 2021 --> May 2023
- |||||||||| Empliciti (elotuzumab) / AbbVie, BMS, Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal, Trial primary completion date: ESdRRMM: Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma (clinicaltrials.gov) - May 4, 2022
P2, N=0, Withdrawn,
Trial completion date: Feb 2022 --> Dec 2024 | Trial primary completion date: Nov 2021 --> May 2023 N=18 --> 0 | Trial completion date: Jan 2024 --> Apr 2022 | Initiation date: Jan 2022 --> Apr 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2023 --> Apr 2022
|
